1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
41.47 USD   +2.80%
08/12Novavax COVID-19 Vaccine Receives Approval in South Korea for Use in Adolescents
MT
08/12Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
PR
08/12Novavax Vaccine Approved for Adolescents in South Korea
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

The next COVID booster shots will likely be updated for Omicron

06/24/2022 | 07:00am EDT

NEW YORK, June 24 (Reuters) - COVID-19 vaccines this fall are likely to be based on the Omicron variant of the coronavirus rather than the original strain, although some experts suggest they may only offer significant benefits for older and immunocompromised people.

Moderna, Pfizer and Novavax have been testing vaccines based on the first BA.1 Omicron variant that became dominant last winter, driving a massive surge in infections.

On Wednesday, Moderna said its updated vaccine worked well against more recent Omicron subvariants, and that it was moving forward with plans to ask regulators for approval.

Vaccines that can bridge the gap between the original version of coronavirus and the Omicron variant would likely be "far, far better" for the fall, according to Trevor Bedford, a biologist at the University of Washington who has closely tracked mutations of the SARS-coV-2 virus.

Bedford said it would take too long to meet regulatory requirements for a switch to tailor the next vaccine to versions of Omicron spreading quickly now.

"Catching up to any of the Omicrons is really important," he said, noting the enormous jump in the number of mutations from the original strain that emerged in China to Omicron on the spike protein part of the virus the vaccines target.

The World Health Organization (WHO) plans to assess the effectiveness of vaccines built for Omicron, as do national health regulators like the U.S. Food and Drug Administration.

A group of WHO advisers said last week an Omicron-based vaccine may broaden immunity after the Omicron variant evaded much of the protection against infection generated by the vaccines designed for the original virus, a view other experts share. FDA scientific advisers will meet on June 28 to make a recommendation on the issue.

Important questions remain, including whether vaccines designed for variants circulating last winter will work well against significantly different subvariants that may emerge. Experts also want to know if the new shots will increase protection against severe disease and death for younger, healthier people or merely offer a few months additional safeguard against mild infection.

Scientists who have questioned the value of booster shots for young and healthy people say a broad campaign is not needed with an updated shot either.

BILLIONS OF DOLLARS AT STAKE

Unlike annual adjustments for influenza vaccines that manufacturers are allowed to try to align with circulating strains, regulators have asked companies to run clinical trials to prove their new COVID vaccines work better.

But nearly three years into the pandemic, vaccine makers are pushing for a flu-like model that would allow them to nimbly retool their shots to combat new variants.

At stake are billions of dollars in contracts with countries around the world. Moderna is already manufacturing the shots, with deals signed in some countries.

Moderna is asking regulators to greenlight a version of their COVID-19 shot targeting both the BA.1 Omicron variant and the original version of the virus, armed with fresh evidence it may be effective against more recently circulating subvariants.

"The challenge we have is the virus continues to evolve really quickly,” Moderna President Stephen Hoge said in an interview, noting that millions of doses of the updated vaccine could be ready in August.

If the drugmaker needs to tweak the vaccine further and restart manufacturing, new shots may not be available until the middle of the fourth quarter, he said.

Pfizer and partner BioNTech are testing variant-adapted COVID-19 vaccines but have yet to release any data. Novavax, whose vaccine is not yet authorized for U.S. use, launched a trial of its own Omicron-based vaccines in late May.

Dr. Jesse Goodman, a professor at Georgetown School of Medicine and a former top FDA scientist, said unlike for flu, regulators do not have enough experience with COVID vaccines to match them to circulating strains without clinical trials.

Dr. Luciana Borio, former acting chief scientist of the FDA, said the science generally supports the idea that it would be better to have vaccines that more closely match the currently circulating virus.

"We see that with people that have hybrid immunity from vaccination plus infection," Borio said. "The immune response that is generated is very rich."

Still, Borio and others are not convinced everyone should be vaccinated again.

"There's no evidence that a healthy 27-year-old person needs to be revaccinated," Borio said.

(Reporting by Michael Erman Editing by Caroline Humer and Bill Berkrot)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.11% 160.35 Delayed Quote.-37.80%
MODERNA, INC. -0.37% 171.18 Delayed Quote.-32.60%
NOVAVAX, INC. 2.80% 41.47 Delayed Quote.-71.01%
PFIZER, INC. 3.77% 50.11 Delayed Quote.-15.14%
All news about NOVAVAX, INC.
08/12Novavax COVID-19 Vaccine Receives Approval in South Korea for Use in Adolescents
MT
08/12Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescent..
PR
08/12Novavax Vaccine Approved for Adolescents in South Korea
DJ
08/11Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
PR
08/10Novavax Gets Thai Regulator's Emergency Use Authorization for COVID-19 Vaccine for Ages..
MT
08/10B. Riley Securities Lowers Novavax's Price Target to $126 from $171 After Lower-than-Ex..
MT
08/10Novavax, Serum Institute Of India Receive Expanded EUA For Novavax’ Covid-19 Vaccine In..
RE
08/10Novavax - expanded eua is based on data from the ongoing pediatr…
RE
08/10Novavax and serum institute of india receive expanded eua for no…
RE
08/09NOVAVAX : Reports Second Quarter 2022 Financial Results and Operational Highlights - Form ..
PU
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 2 379 M - -
Net income 2022 319 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 10,5x
Yield 2022 -
Capitalization 3 244 M 3 244 M -
EV / Sales 2022 0,31x
EV / Sales 2023 -0,04x
Nbr of Employees 1 541
Free-Float 98,8%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 41,47 $
Average target price 125,83 $
Spread / Average Target 203%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-71.01%3 244
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068